For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology ...

Management guided INGREZZA sales to reach between $2.5 billion and $2.6 billion in 2025, supported by an expanded sales force and ongoing direct-to-consumer initiatives. This guidance reflects ...

Neurocrine stock tumbled late Thursday after the company issued lackluster guidance for its bread-and-butter product, Ingrezza.Please watch the video at Investors.com - How To Buy Stocks: ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology ...